Investor Presentaiton
Financial Results for FY2022
Financial Results for FY2022 (Core Basis)
(Ref.) Earnings related to Sumitovant
Billions of yen
Billions of yen
FY2021
FY2022
Change
FY2022
FY21
FY22
Jan. 31
Results
Results
Value
FX impact
%
Revenue
35.7
89.7
forecasts
Revenue
Cost of sales
Gross profit
SG&A expenses
R&D expenses
Other operating income/expenses
Core operating profit
Changes in fair value of contingent
560.0
555.5
(4.5)
60.5
(0.8)
563.0
SG&A expenses *
90.3
139.5
157.1
176.7
19.6
18.4 12.5
173.0
R&D expenses
24.3
33.7
402.9
378.8
(24.1)
42.1 (6.0)
390.0
Core operating profit
(86.9) (96.8)
251.6
305.6
54.1
39.7 21.5
308.0
Operating profit
(86.5) (97.7)
94.0
106.1
12.1 12.7 12.8
98.0
Net profit
(87.4)
(103.9)
1.2*1
49.2
48.0
4.2
50.0
Net profit attributable to
(71.6) (81.7)
owners of the parent
58.5
16.4
(42.1)
(6.2) (72.0)
34.0
3.3
3.4
0.1
1.0
consideration (negative number indicates loss)
Other non-recurring items
(negative number indicates loss)
(1.6) *2 (96.7)
(95.2)
Operating profit
60.2
(77.0) (137.2)
(27.0)
Finance income/costs
22.7
29.1
6.3
Profit before taxes
Income tax expenses
Net profit
Net profit attributable to owners
83.0
(47.9) (130.9)
42.4
48.8
6.4
40.6
(96.7) (137.3)
56.4
of the parent
(74.5) (130.9)
The figures include intra-group transaction
* Include amortization of patent rights
(62.0) *1 Breakdown of other operating income/expenses
1 Share transfer of Sumitomo Pharma Food &
Chemical
2 Sale of Priority Review Voucher
③ Divestiture of BROVANAⓇ and XOPENEX HFA®
4 Divestiture of LUNESTAⓇ
*2 Breakdown of other non-recurring items
①Impairment loss on KYNMOBIⓇ : ¥55.6B
2 Impairment loss on TP-0903 : ¥20.6B
(35.0) ③Restructuring expenses in North America : ¥12.7B
Average rates:
Period end rates:
Sumitomo Pharma
FY2021 Results:
FY2022 Results :
FY2022 forecasts:
1US$ ¥112.40, 1RMB = \17.52
1US$ ¥135.51, 1RMB = \19.75
1US$ ¥135.00, 1RMB = ¥19.50
As of the end of March 2022: 1US$ = ¥122.41, 1RMB = \19.26
As of the end of March 2023: 1US$ = ¥133.54, 1RMB = ¥19.42
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
3View entire presentation